contrast agent injector

Innovating Cancer Care: Bayer’s Low-Dose Contrast Enhanced MRI

Advancing radiology for smart imaging

Bracco at ECR 2025: Innovations in Contrast Media and Sustainability

At ECR 2025, Bracco Imaging showcased two major developments aimed at improving contrast media efficiency, and improving patient safety.

Bracco brings actionable solutions for ‘Planet Radiology’ to ECR 2025

Fabio Tedoldi from Bracco Imaging shares some highlights of their collaboration with the Dutch company Zereau at ECR.

Bayer at ECR 2025: Shaping Radiology with Contrast & AI

At the ECR 2025 Bayer highlights the promising phase three trial data for the MRI contrast agent Gadoquatrane.

Positive results from Phase III study for Bayer’s investigational contrast agent gadoquatrane

SIRM2024: Bracco on New Contrast & Trends in EMEA